Eric Honroth
President and Chief Executive Officer
Eric Honroth  image

Eric Honroth joined AngioDynamics as President and Chief Executive Officer in 2026, bringing more than 20 years of leadership experience in the medical device and life sciences industries. 

Prior to joining AngioDynamics, Honroth served as Global President, Life Science at Getinge, where he held full P&L responsibility for an approximately $600 million global business with approximately 1,200 employees. In this role, he oversaw commercial operations, research and development, global manufacturing, innovation, quality and regulatory compliance, finance, and sustainability. Earlier at Getinge, he served as President for the North American Sales and Service division, leading the company's largest region managing 1,650 employees and $1.4 billion in revenue. Honroth was responsible for a diverse product portfolio spanning Cardiovascular, ECMO, Ventilation, major capital equipment, consumables, software, and service offerings. 

Prior to Getinge, he held senior leadership positions at BD and Abbott. At BD, Honroth served as National Vice President of Sales for the Medical Surgical division. At Abbott, he served as General Manager of Abbott Vascular’s international Cardiology business in Canada, as well as Director of Sales for the Eastern Area in Endovascular and Senior Director of U.S. Commercial Operations and Strategic Planning. His experience spans cardiovascular, endovascular, urology, and life sciences markets across both U.S. and international businesses. 

Honroth earned a Bachelor of Science degree from Miami University in Oxford, Ohio. 
 

Stephen A. Trowbridge
Executive Vice President and Chief Financial Officer
Stephen A. Trowbridge

Stephen A. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having served as Interim Chief Financial Officer since October 2019. Prior to his appointment as Chief Financial Officer, he served as the Company’s Senior Vice President and General Counsel. He joined AngioDynamics in June 2008 as Corporate Counsel. 

In addition to serving as the Company’s CFO and managing the finance functions,
Mr. Trowbridge also manages the Legal function on an interim basis. Mr. Trowbridge also oversees the Company’s clinical affairs, medical affairs and healthcare economics departments. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. 

Mr. Trowbridge began his career with Cadwalader, Wickersham & Taft LLP in the firm’s Mergers and Acquisitions and Securities Group. Mr. Trowbridge received a Bachelor of Science in Science and Technology Studies from Rensselaer Polytechnic Institute, a Juris Doctor from the University of Pennsylvania Law School, and a Master of Business Administration from Duke University’s Fuqua School of Business.

Chad Campbell
Senior Vice President and General Manager, Oncology and Interventional Devices
Chad Campbell

Chad T. Campbell joined AngioDynamics in May 2016. He is the Senior Vice President and General Manager for AngioDynamics’ Oncology and Interventional Devices Global Business Units. In his role, Mr. Campbell oversees global commercialization of the Oncology and Interventional Devices global business unit portfolios. Mr. Campbell joined AngioDynamics from Medtronic, serving as Vice President of Marketing for the Patient Care and Safety business after serving as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic). During his tenure at Covidien, Mr. Campbell also held roles including Director of Marketing, Area Vice President of Sales, Region Manager, and other sales & marketing roles. Mr. Campbell received a Bachelor of Arts from the University of Kentucky.

Laura Piccinini
Senior Vice President and General Manager, Cardiovascular and International
Laura Piccinini image

Laura Piccinini joined AngioDynamics as Senior Vice President and General Manager for International in June 2021. Ms. Piccinini brings more than 25 years of experience in leadership roles in the Medical Device/Technology industry, with an extensive background in the field of respiratory care. Most recently, she served as CEO & member of the Board of Directors for Respiratory Motion, Inc., and was Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Earlier in her career, Ms. Piccinini served as President of EMEA at both Covidien and Stryker. Ms. Piccinini is a graduate of the Parma University of Medicine, where she received a nursing degree with specializations in ICU, Anesthesia, and First Aid as a Helicopter Flight Coordinator.